Skip to main content

Select Drug Profiles

Practice Management
Frontline Use of Bendamustine plus Rituximab Cost-Effective for Indolent B-Cell Non-Hodgkin Lymphoma
Chase Doyle
Read More
Practice Management
ASCO Value Framework Ill-Equipped to Assess Value of Therapies in Chronic Lymphocytic Leukemia
Chase Doyle
Read More
Multiple Myeloma, Oncology
American Society of Hematology 2016: Multiple Myeloma Highlights
Read More
Leukemia, Oncology
Lenalidomide Maintenance Therapy Extends Progression-Free Survival in Patients with High-Risk Chronic Lymphocytic Leukemia
Wayne Kuznar
Read More
Leukemia, Oncology
Ponatinib, a Tyrosine Kinase Inhibitor, Active in Patients with Relapsed or Refractory Chronic Myeloid Leukemia and BCR-ABL T315I Mutation
Charles Bankhead
Read More
Leukemia, Oncology
CPX-351 Improves Posttransplant Survival in Older Patients with High-Risk Acute Myeloid Leukemia
Phoebe Starr
Read More
Leukemia, Oncology
Strategies to Reduce the Use of Tyrosine Kinase Inhibitors in CML
Phoebe Starr
Read More
Practice Management
New Value Model Incorporates Long-Term Adverse Effects of Cancer Drugs
Chase Doyle
Read More
Multiple Myeloma, Oncology
HIV Drug Shows Promise in Refractory Multiple Myeloma
Charles Bankhead
Read More
Multiple Myeloma, Oncology
Venetoclax plus Bortezomib and Dexamethasone Produces High Responses in Patients with Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Read More
Page 96 of 244
Results 951 - 960 of 2438